An independent peptide reference — no sellers, every claim sourced

Lactoferrin

Also known as Lf, LTF, bovine lactoferrin, apolactoferrin, lactotransferrin

An iron-binding milk protein sold as an oral supplement, with real randomised trial data and genuinely mixed results.

early-clinical Immune & longevity supplement

At a glance

Category
Immune & longevity
Status
supplement
Made from
from milk Isolated from cow's milk or from whey; the supplement is bovine lactoferrin, not the human protein.
Route
oral (capsules, powder, added to formula and foods); topical formulations exist for oral and vaginal use
Half-life
Orally administered lactoferrin is largely degraded in the stomach and small intestine; a fraction survives, particularly in neonates and when the protein is iron-saturated or enterically protected. Systemic plasma half-life of intravenously administered lactoferrin in animals is on the order of minutes. Most of the proposed benefit of oral dosing is therefore attributed to local action in the gut and to fragments such as lactoferricin, not to systemic exposure of the intact protein.
Onset
In the pregnancy anaemia trials, haemoglobin differences were assessed at four weeks
Molecular weight
Approximately 80 kDa (varies with glycosylation and species) 67
Sequence
Approximately 690 amino acids (human Lf 691, bovine Lf 689); a single polypeptide chain folded into an N-lobe and a C-lobe joined by a helical linker, each lobe binding one ferric ion together with a synergistic carbonate ion. Too long to list here.

Bovine lactoferrin is a normal constituent of milk and whey and is sold worldwide as a food supplement and food ingredient. Several bovine lactoferrin preparations hold GRAS (Generally Recognized As Safe) notifications in the United States for use in foods, and it is an authorised ingredient in infant formula in a number of jurisdictions. It is not an approved drug for any indication in the EU or US. Note also that lactoferrin is not a peptide in the sense most of this reference uses the word: it is a full-size ~80 kDa glycoprotein of roughly 690-700 amino acids, taken orally, not an injectable short peptide.

Doping status: Not listed by WADA

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

It is a cow's milk protein, so it is not suitable for people with cow's milk protein allergy and is not a dairy-free source of iron support.

Mechanism of action

Lactoferrin is a transferrin-family glycoprotein found in milk, tears, saliva, mucosal secretions and the specific granules of neutrophils, where it is part of the innate immune system. Each molecule binds two ferric ions with very high affinity (association constant on the order of 10^22 M^-1), and this iron-withholding is the mechanism that is best established: by sequestering free iron it restricts the growth of iron-dependent bacteria and interferes with biofilm formation and bacterial motility.

The N-terminal region carries a strongly cationic patch that binds directly to anionic microbial surface structures, notably lipopolysaccharide in Gram-negative bacteria and lipoteichoic acid in Gram-positive bacteria 8. This binding is iron-independent and can permeabilise bacterial membranes. Proteolysis of this region in the stomach releases lactoferricin, a short cationic peptide that is a considerably more potent direct antimicrobial than the parent protein 8. Antiviral activity has been reported in vitro against a range of enveloped viruses and is generally attributed to lactoferrin binding heparan sulphate proteoglycans on the host cell surface and thereby blocking viral attachment, rather than to any action on the virus itself.

The iron-status effect - the indication with the strongest human data - is the most counter-intuitive part. A protein that withholds iron nevertheless raises haemoglobin in iron-deficiency anaemia. The proposed explanation is that lactoferrin delivers iron via specific intestinal lactoferrin receptors in a form that bypasses the ordinary ferrous absorption route, and that it lowers hepcidin-driven inflammatory blockade of iron release, so that iron already in stores becomes available. Both explanations are plausible and neither is settled. Importantly, the trials that show benefit compare lactoferrin against ferrous salts, not against nothing, so what is demonstrated is non-inferiority with better tolerability, not a novel iron effect.

Immunomodulatory actions - binding to Toll-like receptor 4 and CD14, modulation of NF-kB signalling, effects on dendritic cell maturation and on IL-6 and TNF production - are well described in cell culture. Whether any of this occurs at the systemic level after an oral dose in an adult, given how little intact protein survives digestion, is not established.

What the research shows

Lactoferrin is one of the few compounds in this category with a genuine randomised controlled trial base, including a trial with more than 2000 participants 4. The result is honestly mixed. For iron-deficiency anaemia in pregnancy, a meta-analysis of four trials found it at least as good as ferrous sulphate with markedly fewer gastrointestinal side effects 1. For preventing infection in very preterm infants, the promising signal from small trials did not survive the large definitive trial 4. There is little good evidence for the general 'immune support' claims under which it is most often sold to adults.

Research in humans

Iron status: Abu Hashim, Foda and Ghayaty (2017) pooled four randomised trials in 600 pregnant women with iron-deficiency anaemia and found the change in haemoglobin at four weeks favoured oral bovine lactoferrin over oral ferrous sulphate (mean difference 0.77 g/dL, 95% CI 0.04-1.55) 1. The difference was driven by the moderate-anaemia subgroup; in mild anaemia the two were equivalent 1. Gastrointestinal side effects were significantly less frequent with lactoferrin 1, which is the clinically meaningful finding, since intolerance is the main reason oral iron fails in practice. Infection: the ELFIN trial (Lancet, 2019) randomised 2203 infants born before 32 weeks to enteral bovine lactoferrin at 150 mg/kg/day, capped at 300 mg/day, or placebo 4. Late-onset infection occurred in 29% of the lactoferrin group versus 31% of controls (adjusted risk ratio 0.95, 95% CI 0.86-1.04, p=0.233) - no benefit, and no benefit on mortality or other major morbidity 4. That single result runs against the pooled picture: the Cochrane review of the same question, in the version now published, pools 12 trials in 5425 preterm infants and reports a risk ratio of 0.80 (95% CI 0.72-0.89) for suspected or confirmed late-onset sepsis, on low-certainty evidence and with no benefit for necrotising enterocolitis of stage II or above 9. So the largest and most rigorous individual trial found nothing, while the pooled estimate across twelve trials, most of them far smaller, still shows a modest reduction that its own authors grade as low certainty and attribute in part to studies of poor methodology that may inflate the effect. That gap is a reason to treat the pooled figure cautiously rather than the other way round. Smaller trials exist in Helicobacter pylori eradication (as an adjunct to standard therapy), in bacterial vaginosis, and in respiratory infection incidence; these are generally small, heterogeneous in dose and preparation, and not decisive. Trials during the COVID-19 pandemic were mostly small, of variable quality, and did not establish benefit.

Animal and lab research

Extensive. Oral bovine lactoferrin has reduced bacterial colonisation and translocation in rodent infection models, reduced colitis severity in chemically induced colitis, and shown anti-tumour activity in azoxymethane-induced colon carcinogenesis in rats. Antiviral and antifungal activity is well documented in vitro. The main limitation is the same throughout: doses in animal studies are frequently far above what a human supplement provides on a per-kilogram basis, and in-vitro antimicrobial concentrations often exceed anything achievable in a human bloodstream after an oral dose.

Caveats. The preparations differ substantially between studies - bovine versus human, apo- (iron-free) versus holo- (iron-saturated) versus native, with different degrees of iron saturation and different glycosylation - and these are not pharmacologically interchangeable, yet trials and supplement labels frequently do not specify which was used. Doses in trials range from 200 mg per day (100 mg twice daily) to 250 mg per day for iron indications, and 150 mg/kg/day capped at 300 mg/day in ELFIN 4, so the schedules are not directly comparable even before the preparations differ. Several of the pregnancy anaemia trials come from a small number of centres, mostly in Egypt and Italy, and blinding is not always adequately described. Almost all the positive human data concern two specific populations - anaemic pregnant women and preterm infants - and generalising to healthy adults taking a capsule for 'immunity' is not supported. Oral bioavailability of the intact protein in adults remains poorly quantified, which undermines any claim about systemic immunomodulation.

What it is used for

  • Iron-deficiency anaemia, particularly in pregnancy, where it is used as a better-tolerated alternative to ferrous salts 12
  • Added to infant formula as a component naturally present in human milk
  • Studied in very preterm infants for prevention of late-onset infection: the largest trial found no benefit 4, while the pooled Cochrane estimate across twelve trials still shows a modest reduction on low-certainty evidence 9
  • Adjunct in Helicobacter pylori eradication regimens, on limited data
  • Sold to adults as general immune support and gut health support - the least well-supported of its uses
  • Topical and oral-care formulations for antimicrobial effect

Dosing

Dose
In the pregnancy anaemia trials, 100-250 mg per day of bovine lactoferrin taken orally — commonly 100 mg twice daily, and 250 mg once daily in one trial. Consumer supplements typically supply 250-600 mg per day. The ELFIN preterm infant dose is a weight-based neonatal figure and is set out separately below.
Frequency
once or twice daily
Route
oral, preferably on an empty stomach or away from food to reduce proteolysis; some products use enteric coating or liposomal encapsulation for the same reason
Duration
4-8 weeks in the anaemia trials; ELFIN dosed until 34 weeks postmenstrual age
  • The 100 mg twice daily figure comes from Nappi and colleagues (Acta Obstetricia et Gynecologica Scandinavica, 2009), who randomised 100 pregnant women to 100 mg bovine lactoferrin twice daily or 520 mg ferrous sulphate once daily 2. A separate 2015 randomised trial used 250 mg once daily for eight weeks 3. Both are genuinely trial-derived, which is unusual in this reference, but they are different schedules and should not be blended into one.
  • The ELFIN neonatal dose was 150 mg per kg per day with a maximum of 300 mg per day, given enterally until 34 weeks postmenstrual age 45. That cap matters: without it the per-kilogram figure reads as unbounded, and it is in any case a dose for infants born before 32 weeks, not a figure to scale up to an adult body weight.
  • Consumer doses are frequently higher than the trial doses without any evidence that more is better.
  • Apo-lactoferrin (iron-free) and holo-lactoferrin (iron-saturated) are different products. For iron repletion the iron-carrying form is the relevant one; for iron-withholding antimicrobial effect the iron-free form is. Labels often do not say which is supplied.
  • Lactoferrin binds iron, so timing relative to other iron supplements and to foods high in iron is not a neutral question and has not been systematically studied.
  • Dosing in pregnancy should be a matter for the treating clinician, not self-directed; anaemia in pregnancy needs a diagnosis first.
  • A consumer self-supplementation pattern circulates alongside the trial doses and is set out as a circulating protocol below. The trials used 100-250 mg per day for a diagnosed indication 12; consumers commonly take 250-600 mg per day or more, open-ended, for immune and gut claims the trials did not test. It is recorded because readers encounter it, not because it is validated for that use.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Protocols

Iron deficiency anaemia in pregnancy

published trial

Source: Acta Obstetricia et Gynecologica Scandinavica, 2009 - Nappi et al., bovine lactoferrin versus ferrous sulphate in 100 pregnant women

Daily, over 30 days100 mg bovine lactoferrin orally, twice daily

One of the few genuinely trial-derived doses in this reference. The comparator arm took 520 mg ferrous sulphate once daily; efficacy was equivalent and gastrointestinal side effects were significantly fewer with lactoferrin, which is the clinically meaningful result. A separate 2015 randomised trial used a different schedule, 250 mg once daily for eight weeks, so there is no single 'lactoferrin dose' for this indication. It applies to a diagnosed anaemia managed by a clinician, not to self-directed supplementation, and consumer products commonly supply more without evidence that more helps. Apo-lactoferrin and holo-lactoferrin are not the same product and labels often do not say which is inside.

Very preterm infants (ELFIN)

published trial

Source: The Lancet, 2019 - ELFIN, 2203 infants, randomised placebo-controlled trial

Daily, until 34 weeks postmenstrual age150 mg per kg per day, enterally, to a maximum of 300 mg per day

ELFIN found no reduction in late-onset infection, which did not confirm the more optimistic earlier pooled estimate. This is a neonatal intensive care schedule in infants born before 32 weeks and has no bearing on adult supplement use. Note the 300 mg daily cap: this is a per-kilogram dose with a ceiling, not an open-ended one, and it is not a figure to scale to an adult.

Consumer immune and gut supplementation (circulating)

user protocol — not validated

Source: Supplement retailer labelling and general wellness write-ups

This is not a validated schedule. It is a pattern that circulates among users and sellers, reproduced because it is what people actually follow — not because it has been tested. No trial established these doses, this interval or this duration, and nobody is checking what is in the vial. Treat every number below as an assertion, not a finding.

Commonly sold and taken250-600 mg per day, sometimes higher, taken daily and often indefinitely for 'immune support' or gut health
How it diverges from the trialsthe studied doses were 100-250 mg per day for a diagnosed indication over weeks; consumer use is higher, open-ended and for indications never tested

This is the mildest kind of divergence on this site — an oral food protein rather than an injectable drug — but it is a divergence worth naming. The trial doses above were 100-250 mg per day for diagnosed iron-deficiency anaemia in pregnancy, or a weight-based neonatal dose in preterm infants 124; the label-versus-practice gap is that consumers take more, for longer, for 'immunity' and gut health, which are the least-supported of lactoferrin's uses and generalise the pregnancy and preterm data to a population in which they were never tested. Consumer products commonly supply more than the trial doses without evidence that more helps, and labels frequently do not state whether the product is apo- (iron-free) or holo- (iron-saturated) lactoferrin, which are not interchangeable. Absence of reported harm in this large, unmonitored consumer population is not evidence of safety. Anyone injecting lactoferrin — occasionally floated online — is doing something with no published human basis at all. These figures come from labelling and practice, not from a trial of this use.

Schedules are reproduced as their source states them. Units, IU and milligrams explains why the figures are not interchangeable between products.

Reconstitution

Storage
Powder and capsules are stored cool, dry and away from light. Lactoferrin is heat-labile: pasteurisation and high-temperature processing denature it, so a product's manufacturing route matters more than its milligram count. Refrigeration extends shelf life of bulk powder.

Not applicable - lactoferrin is an oral protein supplement, not a lyophilised injectable peptide, and there is no reconstitution step. Anyone injecting lactoferrin is doing something with no published human basis whatsoever.

Safety

Side effects

  • Generally well tolerated orally; in the pooled pregnancy trials gastrointestinal side effects were significantly less frequent than with ferrous sulphate, which was the point of using it 12
  • Mild gastrointestinal upset, nausea, constipation or loose stools in some users
  • Rash and, rarely, allergic reaction - bovine lactoferrin is a milk-derived protein and is a plausible allergen for people with cow's milk protein allergy
  • Iron overload is a theoretical concern only with sustained high-dose holo-lactoferrin in someone who does not need iron; this has not been reported as a practical problem but has also not been systematically looked for
  • No signal of serious harm emerged in the 2203-infant ELFIN trial, which is the strongest safety evidence available for any dose of this compound 45

Do not use if

  • Cow's milk protein allergy - bovine lactoferrin is a milk protein, isolated from cow's milk or whey
  • Haemochromatosis or other iron-overload states - not because lactoferrin is proven to worsen them, but because deliberately taking an iron-transport protein in that setting has no rationale and has not been studied
  • Galactosaemia and other conditions requiring strict avoidance of dairy-derived material, depending on the specific preparation
  • Use in pregnancy for anaemia should follow a diagnosis and clinician supervision rather than self-treatment

Interactions

Not systematically studied in humans. Because lactoferrin binds two ferric ions with an association constant on the order of 10^22 M^-1 67, concurrent administration with oral iron salts or with iron chelators is pharmacologically non-trivial and unquantified. Theoretical interference with the absorption of other divalent metals (zinc, copper) has been raised but not demonstrated clinically. No cytochrome P450 interactions are expected for a dietary protein.

Sources